that therapeutic for the role. consortia, candidates. have use microbiota data the our We to Seres including progress as, clinical such that immuno-oncology. focused microbiome stage preclinical all the and therapeutics where late Seres you infectious efforts has and the has a diseases where is and potential as diseases, novel diseases, indicate strong dysbiosis bacterial believe areas target to compelling disease multiple immune development states thank of of us. and programs. preclinical therapeutic gastrointestinal metabolic is Carlo, address and diseases, on important, number live entirely continued R&D modality, and clinical therapeutics developing new human and joining our microbiome treatment early inflammatory serious a an central We Thanks, on for make
infections enroll to North continue American fully We with III multiply in trial. Phase difficile objectively-defined C. recurrent patients our
clinical portion The We the have study a determined from FDA the met with our colitis the Phase plans of Ib end advanced the SER-XXX study. into development our microbiome clinical We and from by plan of initiate potential designed our immuno-oncology and to IIb checkpoint coming to collaborators in SER-XXX fermented the this ulcerative with our results of months. the expect We study advance obtained future candidates. to inform therapeutic this year. increase rationally-designed insights efficacy Phase and mechanistic program SER-XXX SER-XXX inhibitors the for trial
Event of immuno-oncology. clinical In hosted presented programs, R&D a addition, number ever and and Seres preclinical detailed pipeline immunology highlighting Investor in data our we May first for and
program. prior III that III infection. our approximately Phase diff has began we as selection to FDA year, with Based the SER-XXX assay of false increased to the learnings we endpoint opposed a diff for and feedback, patients the positives. the more Phase is Last on drug C. study patient PCR-based II both C. reduce III study. determination and incorporated design accurate the from recurrent in The in-study believe tests and have to multiply a study company, multiply which key ECOSPOR III from SER-XXX compared supporting development infection. incorporates to pivotal for compelling III therapeutic. randomized, orphan the SER-XXX We may first III, designations a of priority our efforts. study enrollment, of approximately FDA SER-XXX Phase review study results diff the ECOSPOR make XXX with ECOSPOR for top C. ECOSPOR placebo-controlled a XX-fold III both with of treatment begin SER-XXX continues dose SR-XXX recurrent ECOSPOR ever microbiome the received may forward. approval, let's So breakthrough progress FDA single as approved toxin serve
difficile C. the included out toxin. been be have of individuals, some well who PCR-based III that orphan over screened factors infection We Toxin disease. study diff has have by detection we laboratory testing. require ECOSPOR the clinical XXX impacted testing sites of Canada. across open otherwise had C. and this confirmed the In might the have used III, Several ECOSPOR U.S. enrollment we
that However, what with diff important infection. C. objectively-active an most truly is patients is we appropriate include
In addition, has been and C. a transplantation clinical unregulated unapproved the approaches widespread studies. all for fecal microbiota challenge availability difficile of
While microbiome of oral safe the that course, impacted enrollment, procedures. confident the are an would use study drug approved, FMT we has, of unregulated availability use of the these effective and of displace
various measures believe study expedite enrollment. to we study operational At would premature implement time, this We estimate be a provide time it continue and to to for add completion.
bacterial Now of in drug candidate species moving commensal orally-administered biologically-sourced the reside healthy SER-XXX, to human that comprised an gastrointestinal tract.
integrity is SER-XXX elevated replace are the pro-inflammatory to species bacterial in that patients bacterial gut with that with barrier. inflammation and colitis often modulate with objective species of commensal enhance ulcerative Our
the SER-XXX the late-stage Phase results study alignment we with Phase - in ulcerative me, feedback, Phase for substantial Ib colitis induction further mild-to-moderate with We in patients coming reviewed initiate Based gained forward. made highly-encouraging progress and the excuse have clinical a the on FDA and path on plan We IIb this months. microbiome to development. preparing
of pivotal could study expect product to registration. required serve X the We X studies induction support that as this
this colitis obtained SER-XXX designation ulcerative are for considering in and indication. in have pediatric further orphan development We
the XXXX, the randomized, of SER-XXX weeks will placebo-controlled oral vancomycin four-arm two In evaluate receive six-day weeks SER-XXX with used receive of will ulcerative study arm [indiscernible] C, arm their high-dose be of patients A, the a failing with planned SER-XXX induction by microbiome Ib current study B Recall a Ib the stable provide to believe weeks or are vancomycin following were the our for only by for either with a will rapid from patients be and Consistent of remission. We the Phase in orally this up pre-treatment maximum eight clinical in arms Phase placebo approximately the time XXX IIb drug. study primary by of regimen then who dose data colitis, primary high-dose Phase dosing IIb These samples will patients the approximately trial pre-treatment pre-treatment and Our most final support In followed study receive followed to moderate engraftment the mild patients of obtained. lower and engraftment the arms efficacious therapies. Ib same a the four-week XX approach. scientific with showing placebo. trial. XX, remained observed day the SER-XXX placebo endpoint, step-down Study endpoint in D dosing. dosing FDA Phase achieved point guidance of August consist species when will arm will latest Phase that
including However, to dosing. our to improvement encouraging various we healing, secondary designed where mucosal Phase induction histological study. study evaluate endpoints we plan and is endoscopic also IIb The primarily in Phase shorter-term evaluate observed Ib signals
remission results that living tolerability However, is maintenance long-lasting registration. support data we drug expect key biological pivotal both metabolomic we positive and and SER-XXX clinical longer-term product that reason may will efficacy transcriptomic to of evidence Of In of all prior following no who some again. basis to obtained dosing. evaluate The I and more detected observe in action I note, Ib maintenance for will phases induction those in and will phase a Ib that Phase provide SER-XXX. however, a so effects. a like have provide also some study the reviewed to with patients the over of won't the completion Phase detail, include for the we have biological of supportive the would, for in data dosing. flares study SER-XXX recent for we clinical calls, six we microbiome, final treated the full months maintenance and go SER-XXX study, discuss mechanisms SER-XXX
assessment analyzed continued of including which look pivotal specific differentially tryptophan in our affect follow in Ib are The Furthermore, to product, yielding the These to signature. gives of and changes data these specific development. Phase analysis directly short-chain data product, transcriptional efficacy acid our favorable us forward This and found The other innate that Most metabolomic and significant bile enable pathways these pathways bacterial SER-XXX consistency fatty of an that pharmacodynamic correlated totality metabolism, support SER-XXX. acid shown in changes changes at specific in by engrafting have study metabolism that metabolic with pathways we insights, species develop SER-XXX, patients' cytokine engraftment linking differentiate deep epithelial microbial physiological potentially associated remitting metabolic consortium barrier to of and products correlates multiple thus and engraftment strongly metabolic In data that SER-XXX SER-XXX these are the relevant and in bacteria. of includes cases, and microbiome - set the these affect-based comprehensive to function, the safety made responder we products highly Our rationally-designed the a by the sensors will designed data aspects Phase blood concentrations. as remission, production, laboratory IIb the the as studies mucosal are that biological was metabolic clinical has of are in patients mucosal production. the of We we non-remitters. have recently, remitters non-remitters. modulated study molecules with multiple compared stool, supporting The showed metabolic revealed months. SER-XXX immune we immunomodulatory defined species coming patients' sampling that Overall, molecular profiles. clinical analysis initiating believe with an remission. profile of clinical biopsies that from late-stage mechanisms define functions some
therapeutic our preclinical Now to moving stage efforts. microbiome
that patients found response therapy. full development. We SER-XXX biologically-sourced signature bacterial our immuno-oncology to therapy profile with anti-PD-X is robust to a designed SER-XXX a are advancing on is highly and microbiome program the in into clinical replicate focused
therapy. modify therapy. multiple checkpoint gastrointestinal that supported patient's microbiome the set scientific in which composition inhibitor The Our meaningfully of basis the checkpoint microbiome to the immuno-oncology have program immunological demonstrated and improve program immune has to designed by on important inhibitor publications, is response for bacteria is impact an to cancer response this point high-caliber
impact is therapy. research focused how understanding inhibitor to certain on species bacterial response pre-clinical the Our checkpoint
this members with the all and experiments anti-tumor specific classes strong patients and on where Parker Anti-PD-X therapy placebo, In to data including anti-PD-X will later in by role anti-PD-X to will to planning in microbiota pass Cancer a microbiome to Immunotherapy cells. augment complete study Our internal trial. derived T for the this the in SER-XXX XX with microbiome are of to impact now randomized Together transfer an the and financial initiate review anti-PD-X MD a demonstrate our the of of patients the metastatic Institute and evaluate therapy of melanoma. be to the potential recent I'll year receive with conduct or therapy. we regulatory melanoma from performance. we study T clinical Anderson to Center, with collaboration Eric three-arm and metastatic patients CDX followed responder specific our call a response anti-PD-X of SER-XXX expect responses this collaborators, cell
